文献速递免疫规划传染病防控与疫情报告

英国儿童第二年接种MMR时联用或不用灭活疫苗后非特异性住院感染风险:自对照病例系列研究

The risk of non-specific hospitalised infections following MMR vaccination given with and without inactivated vaccines in the second year of life. Comparative self-controlled case-series study in England.
PubMed 文献 · Vaccine · 2019-07-30

该研究采用自对照病例系列方法,比较英国两个日历时期(2002-2006年MMR单独接种 vs 2006-2010年MMR与灭活疫苗同时接种)11-23月龄儿童接种后因感染住院的相对发生率。结果显示两时期接种后90天内相对发生率均为0.94(95%CI 0.91-0.97),两时期相对发生率比值0.94(95%CI 0.87-1.02),无证据支持MMR单独接种降低或联用灭活疫苗增加异源感染风险。

要点

  • 两时期接种后90天内感染住院相对发生率均为0.94(95%CI 0.91-0.97),提示短暂健康接种者效应。
  • 两时期相对发生率比值0.94(95%CI 0.87-1.02),无差异证据。
  • 未发现MMR单独接种降低或联用灭活疫苗增加异源感染住院风险的证据。

核心结论

  • 无证据支持MMR单独接种可降低异源感染,也无证据支持MMR联用灭活疫苗可增加异源感染住院风险。

研究设计与样本

  • 自对照病例系列研究,比较英国两个日历时期11-23月龄儿童接种后感染住院的相对发生率。
  • 时期1(2002年9月-2006年8月)MMR单独接种,纳入21,067名儿童共24,144次感染。
  • 时期2(2006年9月-2010年4月)MMR与PCV7及有时Hib-MenC同时接种,纳入31,616名儿童共36,880次感染。

主要发现

  • 时期1任何感染住院的相对发生率为1.00(95%CI 0.95-1.06),时期2为0.95(95%CI 0.90-1.00)。
  • 两时期相对发生率比值0.94(95%CI 0.87-1.02),无差异证据。
  • 接种后90天内相对发生率时期1为0.94(95%CI 0.91-0.97),时期2为0.94(95%CI 0.91-0.97),符合短暂健康接种者效应。

临床怎么用

  • 为MMR与灭活疫苗同时接种不增加非特异性感染住院风险提供证据,支持现行免疫规划实践。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Observational cohort studies in high-income settings have suggested that vaccination order may affect children's subsequent risk of a heterologous infection, with live vaccines reducing and inactivated vaccines (given on their own or with a live vaccine), increasing the risk. We used the self-controlled case-series method, which automatically controls for the individual level confounding to which such cohort studies are prone, to test this hypothesis. We compared the relative incidence (RI) of infections post-vaccination in two calendar periods in England; in Period 1 (September 2002-August 2006) live measles, mumps, rubella (MMR) vaccine was given on its own and in Period 2 (September 2006-April 2010) inactivated vaccines (7-valent pneumococcal conjugate vaccine (PCV7) and sometimes the combined Haemophilus influenzae type b/meningococcal group C vaccine (Hib-MenC)) were given concomitantly with MMR. Admissions for an infection of the upper or lower respiratory tract, gastrointestinal system or other site in children aged 11-23 months were selected from the Hospital Episode Statistics database in England and linked to child health immunisation histories. The analysis included a total of 24,144 infections in 21,067 children in Period 1 and 36,880 in 31,616 children in Period 2. The RI of admission for any infection in Period 1 was 1.00 (95% confidence interval 0.95-1.06) compared with 0.95 (95% confidence interval 0.90-1.00) in Period 2. Comparing the two periods showed no evidence of a difference in the relative incidence estimates with a ratio of RI of 0.94 (95% confidence interval 0.87-1.02), RIs within 90 days of vaccination were 0.94 (0.91-0.97) in Period 1 and 0.94 (0.91-0.97) in Period 2, consistent with a temporary healthy vaccinee effect. In conclusion, we found no evidence to support the hypothesis that there is a reduction in heterologous infections after MMR on its own or an increase after MMR given concomitantly with an inactivated vaccine.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Andrews N, Stowe J, Thomas SL, et al. The risk of non-specific hospitalised infections following MMR vaccination given with and without inactivated vaccines in the second year of life. Comparative self-controlled case-series study in England. Vaccine. 2019. PMID: 31375437. doi:10.1016/j.vaccine.2019.07.059

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。